Marginal zone lymphoma (MZL) is a rare group of non-Hodgkin’s lymphomas that affect a type of immune cell called B-cells. These MZLs are called low-grade as they are slow-growing and might not always cause symptoms. Some broad symptoms of MZLs are unexplained weight loss, night sweats and fever, however patients are often diagnosed with MZL when they are undergoing tests to investigate something else. Treatment of MZL involves watching and waiting to see how the lymphoma progresses over time with treatment being initiated when the condition worsens (relapses). If the lymphoma persists despite treatment this is known as being refractory. There is currently an unmet need for improved safety of treatment options.
Parsaclisib is an oral selective inhibitor of a protein that can increase B-cell growth and survival, which is a problem in MZL. Parsaclisib is in clinical development for the treatment of patients with relapse or refractory MZL who have never received treatment with a Bruton’s tyrosine kinase (BTK) inhibitor or have been previously treated with this.
Afamitresgene autoleucel is in clinical development for the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) in patients who have previously had chemotherapy. Both synovial sarcoma and MRCLS are two different types of soft tissue sarcomas (STS), a rare form of cancer that develops in the tissues that connect, support and surround other …